SLC3A2 and cancer: cytotoxic-T-cell-driven immunity promotes ferroptotic cell death in cancer cells, which is observed in T cell-driven antitumor immune response launched by immunotherapy with ICIs, mechanistically because of IFN-γ launching the JAK-STAT1 pathway and reducing SLC3A2, SLC7A11.